Cyramza-100 (Ramucirumab Vials) 100mg/10ml

CYRAMZA (ramucirumab) 100mg/10ml vials are an intravenous infusion used alongside other therapies. This VEGF inhibitor supports cancer treatment by targeting blood vessel growth in tumors. Short-term storage at 2–8°C preserves potency until use. Always consult a healthcare provider for personalized guidance.

Strength

100mg/10ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

ELI LILLY (SUISSE) SA

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

CYRAMZA (ramucirumab) is a targeted therapy used to slow tumor growth in certain cancers. It is commonly prescribed alongside chemotherapy for advanced gastric cancer, colorectal cancer, or non-small cell lung cancer. Patients may receive it when other treatments have not been effective. The 100mg/10ml vial strength supports precise dosing in clinical settings.

Side Effects

As a VEGF receptor antagonist, ramucirumab helps reduce blood supply to tumors, potentially slowing their progression. Patients may experience fatigue or nausea during treatment. Regular monitoring by healthcare professionals helps manage any side effects that arise. Individual responses can vary based on treatment plans.

Precautions & Warnings

Store CYRAMZA vials refrigerated between 2–8°C and protect from light. Avoid freezing or shaking the vial. Use within the recommended timeframe after preparation to maintain sterility. Healthcare providers should follow aseptic techniques during preparation and administration. Patients should report any unusual symptoms immediately.

Avoid Interactions

Ramucirumab may interact with other medications that affect blood pressure or blood clotting. Combining it with certain chemotherapy drugs could increase side effects like fatigue or nausea. Patients should inform their doctor about all prescription, over-the-counter, and herbal products they are using. Alcohol consumption may exacerbate treatment-related side effects.

References

Frequently Asked Questions

CYRAMZA (ramucirumab) is used to treat certain advanced cancers by slowing tumor growth.

It is given as an intravenous infusion in a clinical setting by healthcare professionals.

Common effects may include fatigue, nausea, or high blood pressure during treatment.

No, CYRAMZA vials must be kept refrigerated between 2–8°C until use.

No, it is a targeted therapy that works differently from standard chemotherapy.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.